[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-and-obesity-related-medical-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-and-obesity-related-medical-conditions":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,40,70,105,135,161,182,209,243,275,295,320,347,378,401,427,450,480,507,537,558,584,622,643,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100584833","five-plus-year-efficacy-of-endoscopic-sleeve-gastroplasty-esg-for-sustained-weight-loss-100584833",false,"NCT06894498","Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss","LIGHT","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age at the time of the ESG procedure\n* Subject with a BMI between 30 kg\u002Fm2 and 50 kg\u002Fm2, inclusive, at the time of the primary ESG procedure using Overstitch Endoscopic Suturing System\n* Subject completed follow-up 1-year from the ESG procedure for weight loss management\n* Subject completed or is eligible for follow-up 5-years from the ESG procedure for weight loss management (visit can be collected either retrospectively or prospectively)\n* Subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure.\n* Subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate)\n* Subject is able to read, understand, and sign a written Informed Consent Form to participate in the study\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The objective of this study is to assess the long term weight loss and weight loss journey of patients who received an Endoscopic Sleeve Gastroplasty (ESG) 5 or more years prior to enrollment.",[25,26],"Obesity and Obesity-related Medical Conditions","Weight Loss","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2026-03-31",{"date":35,"type":21},"2026-12",{"name":37,"class":38},"Boston Scientific Corporation","INDUSTRY",8,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100587125","phase-1-a-study-of-met233-in-combination-with-met097-in-individuals-with-obesity-or-overweight-with-or-without-diabetes-100587125","NCT06924320","A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes","A PHASE 1\u002F2A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MET233 CO-ADMINISTERED WITH MET097 IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT INCLUDING PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS","Inclusion Criteria:\n\n* Adult males or females aged 18 to 75 years (inclusive) at the time of screening.\n* BMI ≥27.0 kg\u002Fm2 and ≤38.0 kg\u002Fm2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg\u002Fm2 and ≤45.0 kg\u002Fm2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg\u002Fm2 and ≤45.0 kg\u002Fm2 (inclusive) at Screening for Parts G.\n* Participants must be in generally stable health, as determined by the investigator based on medical history, physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).\n\n  * Participants must have no clinically significant diseases or clinically significant findings on the physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).\n  * Participants in Parts C must not have clinically significant diseases except type 2 diabetes mellitus (T2DM), sleep apnea, well-controlled hypertension, and\u002For dyslipidemia.\n  * Participants in Parts E and G must not have any clinically significant diseases except hypertension, dyslipidemia, and\u002For a clinical diagnosis of sleep apnea.\n* Willing and able to comply with all scheduled study visits, procedures, and required assessments.\n* Women of childbearing potential must be willing to comply with protocol-specified contraceptive requirements and must not plan to become pregnant during the study.\n\nExclusion Criteria:\n\n* Female who is lactating or who is pregnant according to the pregnancy test at Screening or on Day 1. Unwillingness or inability to comply with protocol-specified contraceptive requirements.\n* Clinically significant abnormalities in laboratory results in the opinion of the investigator, increase risk or interfere with study participation.\n* Seated blood pressure higher than 160\u002F100 mmHg at the Screening visit or prior to the first study drug administration.\n* Elevated resting pulse greater than 100 beats per minute at Screening visit or prior to the first study drug administration.\n* Estimated glomerular filtration rate (eGFR) \\\u003C80 mL\u002Fmin at the Screening visit.\n* Diagnosis of Type 1 diabetes.\n* For Part A, Part B, Part D, Part E and Part G: Diagnosis of T2DM or glycated hemoglobin (HbA1c) \\> 6.4% or fasting plasma glucose \\>126 mg\u002FdL at the Screening visit or history of taking any medications to lower glucose.\n* For Part A, Part B and Part D: Participant reported weight-related comorbidity, including sleep apnea and cardiovascular disease.\n* Use of prohibited prescription or non-prescription medications, supplements, or investigational products within protocol-defined washout periods.\n* History or presence of clinically significant gastrointestinal, endocrine, respiratory, renal, hepatic, hematologic, neurologic, cardiovascular, psychiatric, immunologic, or other systemic diseases, except where explicitly permitted by the protocol.\n* Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome, pancreatitis, or pancreatic cancer.\n* History of acute or chronic pancreatitis or pancreatic cancer.\n* Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration or plans to do so.\n* History of bariatric or weight-loss surgery.\n* Clinically significant psychiatric illness that may interfere with study participation or safety.\n* Screening assessments indicative of moderate to severe depression.\n* History of drug or alcohol abuse or dependence within the past 2 years.",true,"75 Years",{"count":50,"type":21},381,"INTERVENTIONAL",[53,54],"PHASE1","PHASE2","This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.",[25],[58,59],"GLP-1","Metsera","2026-05-28",{"date":62,"type":31},"2026-06-01",{"date":64,"type":31},"2025-03-06",{"date":66,"type":21},"2026-09-15",{"name":68,"class":38},"Pfizer",1,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":47,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":51,"phases":81,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":69},"100596775","advancing-biopsychosocial-care-training-initiative-100596775","NCT07049861","Advancing Biopsychosocial Care Training Initiative","Increasing Access to USPSTF-Recommended Obesity Care for Youth and Adults Who Are Recipients of Medicaid: Evaluation of a Comprehensive Multidisciplinary Obesity Care Training Program in FQHCs","ABC Initiative","Study Eligibility Criteria - Provider Trainees:\n\n* Provider Trainees must be PCPs, BHPs, RDNs, or CHWs who work at participating clinics.\n\n  * PCPs that are eligible to participate as Provider Trainees can be any of the following: Medical Doctors (MD), Doctor of Osteopathic Medicine (DO), Physician Assistants (PA), or Nurse Practitioners (NP). PCPs must see patients in a primary care setting and be capable of referring patients to IBT and MNT. PCPs must have already completed their residency (when applicable).\n  * BHPs that are eligible to participate as Provider Trainees must be at least one of the following categories (listed with typical credentials): Licensed Clinical Social Worker (LCSW), Licensed Professional Counselor (LPC), Licensed Marriage and Family Therapist (LMFT), Psychologist (PhD\u002FPsyD), Psychiatric Nurse Practitioner, Psychiatrist (MD).\n  * RDNs that are eligible to participate as Provider Trainees must be Registered Dietitians\u002FRegistered Dietitian Nutritionists.\n  * CHWs must work as Community Health Workers, or in functionally similar role, within participating clinics\n\nStudy Eligibility - EHR Patients: Benefit-Eligible Patients from Participating Clinics\n\n* Benefit-Eligible Patients from Participating Clinics can either be youth (ages 5-20) or adults (ages 21+) and must be recipients of Medicaid, eligible for the MO Medicaid benefit (i.e., Medicaid recipients with obesity), and have been seen at participating FQHC clinics.\n\nExclusion Criteria - Provider Trainees:\n\n* Not at a participating clinic\n* PCPs who do not have the ability to refer to IBT or MNT\n* Resident Doctors\n* A doctor specializing in reproductive health (or related fields)\n\nExclusion Criteria - Benefit-Eligible Patients from Participating Clinics:\n\n* Patients without obesity\n* Patients not on Medicaid\n* Youth under the age of 5\n* Not a patient at a participating clinic","5 Years",{"count":80,"type":21},6200,[82],"NA","This project will compare two training approaches for US Preventive Services Task Force recommended obesity care in Federally Qualified Health Centers (FQHC) across four aims. Aim 1 compares patient-level effectiveness \\[i.e., patient relative weight change and the proportion of patients who achieve clinically significant weight loss\\]. Aim 2 compares reach (patient treatment utilization). Aim 3 compares primary care provider (PCP) referrals to USPSTF-recommended care at 12 (adoption) and 24 months (maintenance) and short- and long-term changes in provider obesity care competencies . Aim 4 compares implementation and service costs.",[85,86,25,87,88],"Weight Management","Obesity Prevention","Obesity and Overweight","Obesity",[90,91,92,93,88,94],"Training","Implementation","Intensive Behavioral Treatment","Family-based Behavioral Treatment","Obesity Care","2026-05-18",{"date":97,"type":31},"2026-05-20",{"date":99,"type":31},"2025-07-14",{"date":101,"type":21},"2028-12-15",{"name":103,"class":104},"Washington University School of Medicine","OTHER",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":51,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":69},"100593837","transition-to-ambulatory-bariatric-surgery-tabs-trial-100593837","NCT07011628","Transition to Ambulatory Bariatric Surgery (TABS) Trial","TABS","Inclusion Criteria:\n\n* BMI ≤ 60 kg\u002Fm2\n* Primary Sleeve gastrectomy or Gastric Bypass,\n* Undergoing bariatric surgery at sponsor site\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Myocardial Infarction\n* Unstable Angina or Heart Failure\n* Prior Stroke\n* Solid organ transplantation\n* Systemic glucocorticoid prior 28 days\n* Severe Obstructive Sleep Apnea\n* Uncontrolled Hypertension (Systolic \\> 150, Diastolic \\> 90)\n* Untreated Hyperthyroidism\n* Chronic Kidney Disease (EGFR \\\u003C 60)\n* Current anticoagulant use,\n* Poorly controlled Type 2 diabetes (Hemoglobin A1c in last 3 months \\> 8.5%)\n* Chronic opioid use\n* Insulin dependence.\n* Need for extended venous thromboembolic event prophylaxis,\n* \\> 1 lifetime bariatric surgery (revisional or conversion bariatric surgery)\n* Patient lives \\> 130 miles from the hospital.\n* Tobacco use in last 12 months\n* Desire to become pregnant or active pregnancy\n* Prisoners\n* Unable or unwilling to follow-up\n* Unable to understand or provide consent","25 Years","55 Years",{"count":115,"type":21},200,[82],"This study will compare same day discharge and at least one night stay in the hospital after bariatric surgery. Patients undergoing bariatric surgery will be randomized (i.e. have an equal chance of either plan) to either group. The study's primary outcome is the frequency patients in the study require a visit to the emergency room within 7 days of their surgery.",[25,119],"Bariatric Surgery",[121,122,123,124],"ambulatory surgery","same day discharge","gastric bypass","sleeve gastrectomy","NOT_YET_RECRUITING","2026-05-17",{"date":128,"type":31},"2026-05-19",{"date":130,"type":21},"2026-07-01",{"date":132,"type":21},"2028-05-01",{"name":134,"class":104},"Vanderbilt University Medical Center",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":51,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":69},"100588949","clinical-research-evaluating-smoking-cessation-with-e-cigarettes-and-nicotine-therapy-100588949","NCT06948058","Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy","CRESCENT","Inclusion Criteria:\n\n* body mass index (BMI) ≥ 30 kg\u002Fm2 (i.e., obese)\n* smoked ≥ 5 cigarettes\u002Fday during the past year\n* 21 or older (due to minimum legal age EC restrictions)\n* exhaled breath carbon monoxide (CO) level \\> 6 ppm at Baseline (BL) (to confirm self-reported smoking)\n* willing to use EC or NRT for 8 weeks\n* access to a Bluetooth-enabled smartphone\u002Ftablet (to permit remote measurement of CO and other outcome variables)\n\nExclusion Criteria:\n\n* received smoking cessation treatment of any kind in the past 30 days (actively quitting smoking),\n* currently using EC or NRT more than 2 days\u002Fweek (this may affect responses to study-supplied products)\n* hospitalized for mental illness in past 30 days\n* heart-related event (e.g., heart attack, severe angina) in past 30 days\n* residing with another person currently enrolled in the study\n* pregnant, nursing, or planning to become pregnant in the next 6 months\n* medical contraindication for study or product use (e.g., allergy to adhesives)\n* taken prescription weight loss medication in the last 30 days","21 Years",{"count":144,"type":21},60,[82],"This project will investigate the effects of alternative nicotine products on smoking, weight gain, and related outcomes.",[148,25],"Smoking Cessation",[150,151,152],"obesity","electronic cigarettes","harm reduction","2026-05-14",{"date":95,"type":31},{"date":156,"type":31},"2025-04-01",{"date":158,"type":21},"2027-08-31",{"name":160,"class":104},"Brown University",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":51,"phases":170,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":69},"100571534","phase-4-2024-tirzepatide-bariatric-surgery-100571534","NCT06721507","2024 Tirzepatide-Bariatric Surgery","Preoperative Tirzepatide for Bariatric Surgery","Inclusion Criteria:\n\n* adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery\n* BMI greater than or equal to 40 kg\u002Fm2 with one or more obesity-related comorbidities\n* have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing\n* enrollment in the ADORE Bariatric Tissue Bank (IRB #69767)\n\nExclusion Criteria:\n\n* any contraindication to the use of tirzepatide (per package insert)\n* Personal or family history of medullary thyroid carcinoma\n* Patients with Multiple Endocrine Neoplasm syndrome type 2\n* Hypersensitivity to tirzepatide\n* History of pancreatitis\n* Type 1 Diabetes\n* patients with active, untreated or symptomatic cholelithiasis or jaundice\n* consistent use of a GLP-1 or GLP-1\u002FGIP receptor agonist, over the past 90 days\n* diagnosed autoimmune disease\n* current use of immunosuppressive agents or use within the past 30 days\n* moderate or severe substance use disorder according to DSM-5 criteria\n* uncontrolled significant psychiatric disorder as assessed by specialized bariatric psychologist\n* female participant who is pregnant, breast-feeding, or intends to become pregnant with in 1 year following surgery\n* a prisoner",{"count":169,"type":21},50,[171],"PHASE4","This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.\n\nThe major objectives are:\n\n1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery.\n2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery.\n\nParticipants will:\n\nTake or not take tirzepatide, depending on what study group they are in, once a week for 3 months.\n\nVisit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug.\n\nKeep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.",[25,119],"2026-05-11",{"date":153,"type":31},{"date":177,"type":31},"2025-03-27",{"date":179,"type":21},"2026-12-31",{"name":181,"class":104},"Marlene Starr",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":47,"sex":17,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":51,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":69},"100568891","egg-intake-metabolic-outcomes-and-choline-levels-100568891","NCT06687122","Egg Intake, Metabolic Outcomes and Choline Levels","Additional Daily Intake of Eggs for Improving Metabolic Outcomes and Choline Levels in Individuals With Obesity: Phase I Study","Inclusion Criteria:\n\n* Male or female participant of any race or ethnicity between 30-65 (inclusive) years of age\n* BMI \\> 30 kg\u002Fm2\n* Non-smoker\n* Willing to consume 3 eggs per day for one dietary period of 4 weeks\n* Willing to avoid eggs during the rest of the study except for eggs that are provided\n* Willing to follow the study protocol including maintaining usual lifestyle during the entire study\n\nExclusion Criteria:\n\n* Age \\\u003C 30 or \\> 65 years\n* BMI \\\u003C 30 kg\u002Fm2\n* Vegans or individuals who do not consume eggs\n* Individuals who are currently pregnant or planning to become pregnant during the course of the study; or are currently breastfeeding\n* Smokers, users of recreational drugs\n* Individuals taking antibiotics or natural health products including prebiotics or probiotics","30 Years","65 Years",{"count":192,"type":21},20,[82],"The purpose of this research is to determine the effect of additional daily egg intake on metabolic phenotypes and metabolism in the context of obesity.",[25],[197,198,88,199,200],"Eggs","Liver health","Metabolism","Gut microbiome","2026-05-09",{"date":203,"type":31},"2026-05-12",{"date":205,"type":31},"2025-01-24",{"date":35,"type":21},{"name":208,"class":104},"University of Guelph",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":69},"100567555","evaluation-of-physical-fitness-and-hemodynamics-across-a-diverse-population-100567555","NCT06669715","Evaluation of Physical Fitness and Hemodynamics Across a Diverse Population","Validation of an Interval Test for Monitoring Cardiovascular Function for Individuals With Different Levels of Physical Fitness","ACT-ON-s1","Inclusion Criteria:\n\n* Adults (18 + years of age) without restriction on sex, health status or physical fitness.\n\nExclusion Criteria:\n\n* Inability to walk without assistance\n* Presence of acute injuries and\u002For illnesses that limit maximal exertion during physical fitness testing\n* Lower extremity injury or surgery within the past 2 years (if not fully rehabilitated)",{"count":218,"type":21},30,"In this study, investigators will use the IFT 30-15 test, a six-minute walking test, and a treadmill test to assess the participants' cardiorespiratory fitness. For the treadmill cardiopulmonary exercise test (CPET), we will measure indirect gas exchange using a CPET device (K5). Maximum heart rate (HRmax) will be measured with a Polar heart rate monitor (model H10). The six-minute walking test will follow standardized procedures, and the treadmill test will follow a protocol of gradually increasing speed each minute.\n\nThe study will involve two groups of participants: healthy individuals and pre-hypertensive individuals. While the IFT 30-15 test has been validated on a diverse range of athletes and physically active individuals, it has not yet been validated in individuals with similar characteristics to our participants (BMI \\> 30 and limited cardiovascular function). Additionally, a variety of hemodynamic measures and other physical function measures such as sit-to-stand and push-ups will be assessed for all participants.",[221,25],"Prehypertension (Elevated Blood Pressure) or Hypertension",[223,224,225,226,227,228,229,230,231,232,233,234],"cardiovascular fitness","CRF","physical fitness testing","vascular function","heamodynamics","blood pressure","prehypertension","aerobic capacity","arterial stiffness","endothelial function","post-occlusive reactive hyperemia","PORH","2026-05-07",{"date":203,"type":31},{"date":238,"type":31},"2024-11-04",{"date":240,"type":21},"2027-10-30",{"name":242,"class":104},"University of Ljubljana",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":69},"100599366","routine-validation-and-reproducibility-testing-of-laboratory-assays-and-research-techniques-used-for-endocrine-cardiometabolic-and-musculoskeletal-disorder-research-vald-100599366","NCT07083557","Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)","VALD","Inclusion Criteria:\n\n* ≥18 and ≤100 years of age\n* body mass index ≥16.0 and ≤60 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C18 and \\>100 years of age\n* body mass index \\\u003C16.0 or \\>60 kg\u002Fm2\n* allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians\n* use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay\u002Ftechniques being evaluated\n* engaged in regular structured exercise \\>150 min per week unless needed for validation of the assay\u002Ftechnique being evaluated\n* significant organ system dysfunction or diseases, except those that are sought for validation of the assay\u002Ftechnique being evaluated\n* alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay\u002Ftechnique being evaluated\n* pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.","100 Years",{"count":20,"type":21},"The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate. Reproducibility means performing the same test more than once to see if the same results can be achieved each time. This study will look at the validation and reproducibility of tests and laboratory assays in participants who are healthy or affected by relevant endocrine, cardiometabolic, and musculoskeletal disorders.",[25,254,255,256,257,258,259,260,261,262,263,264,265,266],"Diabetes","Atherosclerotic Disease","Heart Failure","MASH","Sarcopenia","Osteoporosis","Hyperparathyroidism","Hypoparathyroidism","Ischemic Heart Disease","Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Osteopenia","Cachexia","2026-05-05",{"date":235,"type":31},{"date":270,"type":21},"2027-01-01",{"date":272,"type":21},"2030-07-01",{"name":274,"class":104},"Bettina Mittendorfer",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":281,"targetDuration":4,"studyType":51,"phases":283,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":69},"100572515","early-phase-1-randomized-control-trial-of-sleeve-gastrectomy-with-tirzepatide-in-maximizing-weight-loss-100572515","NCT06734273","Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss","Inclusion Criteria:\n\n* Adult 18 to 65 years of age\n* Body Mass Index \\>35 with comorbidity of Type 2 Diabetes and\u002For Hypertension and\u002For Hyperlipidemia and\u002For Obstructive Sleep Apnea OR Body Mass Index \\>40 with or without comorbidity\n* Undergoing primary sleeve gastrectomy\n\nExclusion Criteria:\n\n* Prior metabolic and bariatric surgery\n* Prior use of GLP-1 agonist\n* Prior history of pancreatitis\n* Personal\u002Ffamily history of medullary thyroid cancer or MEN type 2\n* Secondary cause of obesity\n* Any eating disorder\n* Pregnancy\u002Flactation\n* History of acute coronary syndrome or myocardial infarction\n* History of stroke\n* Hepatic dysfunction: AST\u002FALT \\>3 ULN\n* Renal dysfunction eGFR\\\u003C45ml\u002Fmin\u002F1.73m2\n* Active malignancy\n* History of diabetic retinopathy\n* History of gastroparesis",{"count":282,"type":21},42,[284],"EARLY_PHASE1","This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.",[25],{"date":288,"type":31},"2026-05-08",{"date":290,"type":31},"2025-03-10",{"date":292,"type":21},"2028-09",{"name":294,"class":104},"Nicholas Skertich",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":69},"100634641","the-role-of-autoantibodies-against-g-protein-coupled-receptors-in-obesity-100634641","NCT07542327","The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity","Inclusion Criteria:\n\n* Inhabitant in the Region of Southern Denmark\n* BMI above 30kg\u002Fm2\n* age between 18 and 60 years.\n\nExclusion Criteria:\n\n* individuals previously treated with GLP-1RA medication for any indication\n* Individuals who have previously undergone bariatric surgery\n* Individuals with type 1 diabetes","60 Years",{"count":303,"type":21},160,"The purpose of this study is to explore if GPCR-autoantibodies:\n\n1. are pressent in people living with obesity, and are associated with degree of obesity\n2. if it is associated with obesity related diseases",[88,306,307,25],"Obesity & Overweight","Obesity Type 2 Diabetes Mellitus",[88,309,310],"obesity-related medical conditions","GPCR- autoantibodies","2026-04-21",{"date":313,"type":31},"2026-04-24",{"date":315,"type":21},"2026-09-01",{"date":317,"type":21},"2027-09-01",{"name":319,"class":104},"Claus Bogh Juhl",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":47,"sex":328,"minAge":18,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":51,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100585256","study-of-the-effects-of-time-restricted-feeding-on-the-immune-function-of-individuals-with-obesity-100585256","NCT06899997","Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity","Exploring the Effects of Time-restricted Feeding on the Immune Function of Obese Individuals: Multi-omic Approach","OBESIMM","Inclusion Criteria:\n\nPatients with obesity\n\n* Women\n* Age 18-64 years\n* Body mass Index between 40-50 kg\u002Fm²\n* Self-reported eating pattern window of more than 14h\n* Three meal eating pattern\n* Stable body weight (less than 10% of current body weight during the last 3 months)\n* Social security affiliation\n* Written consent\n* Good understanding of the French language\n\nLean patients\n\n* Women\n* Age 18-64 years\n* Body mass Index between 18.5-24.9 kg\u002Fm²\n* Self-reported eating pattern window of more than 14h\n* Social security affiliation\n* Written consent\n* Good understanding of the French language\n\nExclusion Criteria:\n\n* Diabetes type I or II\n* Major cardiovascular disease\n* Pregnancy\n* Medication that could affect the study outcomes (i.e. anti-inflammatory drugs, antibiotics, immunosuppressors)\n* Use products intended for weight loss\n* Night work shift\n* Past record of malignant tumors\n* Serious liver dysfunction or chronic kidney disease\n* Eating disorders\n* Chronic viral disease (Hepatitis B or C, HIV) or inflammatory systemic diseases (i.e. Crohn's disease, rheumatoid arthritis)\n* Serious cardiovascular or cerebrovascular disease within 6 months before randomization\n* Severe gastrointestinal diseases or gastrointestinal surgery in the 12 months before randomization\n* Under guardianship, curatorship, deprived of liberty\n* Unable or unwilling to sign the informed consent form.\n* Patient on AME (state medical aid)","FEMALE","64 Years",{"count":331,"type":21},24,[82],"The goal of this randomized trial is to: 1) investigate the immunological landscape of patients with obesity and conduct an in-depth functional characterization of their immune system; and 2) precisely define the effects of time-restricted feeding (TRF) on immune function in patients with obesity; 3) uncover the underlying mechanisms by which TRF modulates the immune system patients with obesity through a multi-omics approach.\n\nThe main questions it aims to answer are: i) what is the underlying cause of impaired immunocompetence in patients with obesity? ii) how nutritional interventions improve the immune function of patients with obesity? Patients with obesity following TRF (8 h eating window ranging from 6-8 am to 14-16 pm) will be compared to patients with obesity without TRF control schedule (14h eating window ranging from 6-8 am to 8-10 pm). In addition to patients with obesity, the present study aims to recruit a group of a reference healthy group (BMI between 18.5-24.9 kg\u002Fm²) that will not receive any nutritional intervention.\n\nThe following endpoints will be collected: Body weight and composition using Bioelectrical Impedance Analysis, resting energy expenditure (REE) using indirect calorimetry, blood glucose levels using a continuous glucose monitoring (CGM) device, metabolic parameters (fasting blood glucose levels, C-peptide, HbA1c, insulin, HOMA-IR, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, hepatic enzymes), and cytokine profile.\n\nBlood and stool, samples will be collected to establish metagenomic, transcriptomic, cytomic and metabolomic analyses.",[25],[88,336],"Immune system","2026-04-20",{"date":339,"type":31},"2026-04-23",{"date":341,"type":31},"2025-11-03",{"date":343,"type":21},"2027-09-15",{"name":345,"class":104},"Assistance Publique - Hôpitaux de Paris",2,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":51,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":69},"100595093","phase-4-metabolic-surgery-for-atrial-fibrillation-elimination-100595093","NCT07027969","Metabolic Surgery for Atrial Fibrillation Elimination","Efficacy of Cardiometabolic Risk Factor Control Through Metabolic Surgery on Management and Severity of Atrial Fibrillation: METSAFE Randomized Clinical Trial","METSAFE","INCLUSION CRITERIA\n\nEntry into the study would require that the patient:\n\n1. Is a candidate for general anesthesia\n2. Is eligible for metabolic surgery (RYGB or SG)\n3. Is ≥18 and ≤80 years old\n4. has a BMI ≥35 and ≤65 kg\u002Fm2\n5. has AF criteria, which:\n\n   1. Must be documented by EKG or cardiac monitor or Zio XT Patch\n   2. Must have symptomatic AF\n   3. In terms of types of AF, either paroxysmal AF with at least one episode lasting ≥5 minutes in the last 3 months prior to screening, or persistent AF, or longstanding AF.\n   4. Must have a minimum burden of 1% during a 2-week screening time with an ambulatory noninvasive cardiac monitor.\n   5. Must be assessed and confirmed by an expert cardiologist (e.g., cardiac electrophysiologist) to meet eligibility.\n6. Patients without history of prior AF ablation\u002FPVI procedure or with history of prior failed AF ablation\u002FPVI procedure are eligible for the study.\n7. Patients with and without T2DM are eligible for the study. Patients with T2DM should have been on a stable dose of anti-diabetic medication (including insulin) for at least 3 months prior to entry, with HbA1c ≤12%.\n8. Have the ability and willingness to participate in the study and agree to any of the arms involved in the study.\n9. Able to understand the options and to comply with the requirements of each arm.\n10. Have a negative urine pregnancy test at screening and randomization visits for women of childbearing potential.\n11. Women, of childbearing age, must agree to use reliable method of contraception for 2 years.\n\nEXCLUSION CRITERIA\n\n1. Significant cardiac valvular disease (planned to undergo cardiac valve intervention\u002Fsurgery in the next 12 months)\n2. Significant atherosclerotic disease (planned to undergo coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)\n3. Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V\n4. Classified as New York Heart Association Class IV\n5. Left ventricular ejection fraction \\\u003C20% at the time of screening\n6. Hospitalization for myocardial infarction, unstable angina, stroke, transient ischemic attack, heart surgery, coronary stent placement in the past 6 months\n7. Prior bariatric and metabolic surgery of any kind (patients who had a gastric balloon or gastric band that were removed more than one year prior to enrollment are allowed to participate)\n8. History of solid organ transplant\n9. Type 1 diabetes or autoimmune diabetes\n10. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 at screening or being on dialysis\n11. Decompensated cirrhosis characterized by ascites, hepatic encephalopathy, portal hypertension, or esophageal varices.\n12. Anemia defined as hemoglobin less than 9 g\u002FdL\n13. Use of investigational therapy\n14. Liver transaminase level \\>300 U\u002FL\n15. Significant alcohol use (average \\>2 drinks\u002Fday)\n16. Presence of active malignancy (except non-melanoma skin cancer)\n17. Life expectancy less than 3 years due to concomitant diseases\n18. Major mental health, psychological disorders, or substance abuse disorders that in the opinion of the investigators could disqualify the patient from metabolic surgery\n19. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study\n20. Unable to understand the risks, benefits and compliance requirements of study\n21. Lack capacity to give informed consent\n22. Plans to move outside the primary location of study (Northeast Ohio) within the next 12 months\n23. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures\n24. Known adhesive allergies","80 Years",{"count":20,"type":21},[171],"Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation.\n\nThe purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.",[360,25],"Atrial Fibrillation",[360,119,362,363,364,365,366,367,368],"Metabolic Syndrome","Weight Loss Surgery","Roux-en-Y gastric bypass","Sleeve Gastrectomy","GLP-1 Receptor Agonist","Tirzepatide","Semaglutide","2026-04-16",{"date":371,"type":31},"2026-04-17",{"date":373,"type":21},"2026-11-01",{"date":375,"type":21},"2030-03-31",{"name":377,"class":104},"Ali Aminian",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":385,"targetDuration":4,"studyType":51,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":69},"100587114","utsw-norc-pilot-spinal-cord-injury-dietary-program-100587114","NCT06924177","UTSW NORC Pilot Spinal Cord Injury Dietary Program","Utilizing Dietician-guided Intervention to Combat Neurogenic Obesity in People With Spinal Cord Injury","Inclusion Criteria:\n\n* age 18-65 years old\n* have had SCI for more than one year\n* not independently ambulatory\n* primarily uses a wheelchair for mobility\n* community-dwelling\n* without comorbidities listed in the exclusion criteria\n\nExclusion Criteria:\n\n* uncontrolled type 2 diabetes mellitus\n* pregnancy\n* active systemic disease, e.g., heart disease, real failure\u002Finsufficiency, multiple myeloma, lupus with nephropathy, sickle cell disease, symptomatic myasthenia gravis, poorly controlled hypo- or hyperthyroidism.",{"count":192,"type":21},[82],"The goal of this observational study is to learn about the effects of a 9-week dietician-guided program modified from the National Diabetic Prevention Program (modified DPP-diet) in people with spinal cord injury on body composition and insulin sensitivity.\n\nThe main question it aims to answer is:\n\nDoes 9 week modified DPP-diet reduce body fat percentage and insulin resistance?\n\nParticipants will:\n\nHave 9 weeks of Telehealth visit with dietician certified in providing DPP. Visit the laboratory before, immediately and 9 weeks after completion of the modified DPP-diet.\n\nShare with the researcher on the perceived benefit and obstacles in implementing the modified DPP-diet as part of their daily activities.",[25,389],"Spinal Cord Injury, Chronic",[391,150,392],"spinal cord injuries","insulin resistance","2026-03-26",{"date":33,"type":31},{"date":396,"type":31},"2026-02-13",{"date":398,"type":21},"2026-05-31",{"name":400,"class":104},"University of Texas Southwestern Medical Center",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":408,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":51,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":346},"100564552","a-wearable-device-and-ai-supported-diet-and-exercise-intervention-100564552","NCT06630663","A Wearable Device and AI-Supported Diet and Exercise Intervention","Effectiveness of a Wearable Device and AI-Supported Diet and Exercise Intervention in Obese Adults-a Quasi-experimental Design Study","Inclusion Criteria:\n\n1. At least 20 years of age\n2. BMI ≥24 kg\u002Fm2 plus one or more obesity-related comorbidities such as hypertension, diabetes, hyperlipidemia, sleep apnea syndrome, or nonalcoholic fatty liver disease\n3. Able to use a wearable device and an app\n4. Able to sign the informed consent form after receiving a detailed explanation of the study\n\nExclusion Criteria:\n\n1. Unable to finish the self-administered questionnaires\n2. Unable to complete body composition assessment (bioimpedance analysis and abdominal echo), hand grip test, and blood sampling\n3. Unable to return to our clinics at the scheduled time","20 Years",{"count":410,"type":21},120,[82],"This study implemented a personalized 6-month diet and exercise program to promote weight loss. Participants were recruited from outpatient clinics at the Department of Family Medicine, National Taiwan University Hospital. Overweight and obese adults were eligible, defined as follows: overweight (BMI 24-27 kg\u002Fm²), mild obesity (BMI 27-30 kg\u002Fm²), moderate obesity (BMI 30-35 kg\u002Fm²), and severe obesity (BMI ≥ 35 kg\u002Fm²). Exclusion criteria included recent weight changes exceeding 3%, a history of bariatric surgery, untreated psychiatric disorders, or medications affecting body weight.\n\nStudy design: Of the 171 subjects screened, 29 were excluded due to BMI criteria, leaving 142 participants for baseline body composition and biochemical analysis. Of these, 98 joined the 6-month weight loss program, while 44 remained in the control group. Participants were divided into two groups: one followed a standard diet and exercise program, while the other used a wearable device and AI apps alongside the same program. The wearable device tracked steps, heart rate, and estimated calories burned. Outpatient visits occurred at weeks 0, 12, and 24, with additional diet and exercise education. Phone consultations at weeks 2, 4, and 8 provided 10-minute guidance sessions from case managers. Weight loss medications were not permitted during the study.\n\nData collection: Weight, height, and blood pressure were measured using standard scales and sphygmomanometers. Waist circumference was measured by a trained operator, and bioelectrical impedance analysis was used to assess skeletal muscle, fat mass, and body fat percentage. Blood samples were collected after an 8-hour fast to measure glucose, cholesterol, and triglycerides. Insulin levels were measured, and HOMA-IR was used to assess insulin resistance. Galectin-1 levels were measured using an ELISA kit. Measurements were taken at baseline and at the end of the intervention (week 24).\n\nDiet and exercise intervention: All participants followed a standard diet and exercise program. Those opting for the wearable device aimed for 7,500 steps per day, following World Health Organization recommendations for 150 minutes of moderate aerobic activity per week. Dietary education included caloric intake calculations and Mediterranean diet principles. Participants using wearable devices logged daily steps and food intake, which was uploaded to a health management platform. Case managers provided lifestyle coaching through the platform.",[25],[150,415,416,417],"weight loss","galactin-1","diet and exercise program","2026-03-24",{"date":420,"type":31},"2026-03-25",{"date":422,"type":31},"2025-08-10",{"date":424,"type":21},"2027-12-31",{"name":426,"class":104},"National Taiwan University Hospital",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":51,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":4},"100577212","weight-changes-after-incretin-mimetics-100577212","NCT06795360","Weight Changes After Incretin-mimetics","Inclusion Criteria:\n\n* adults 18 years or older\n* men and women\n* prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse\n* any ethnicity\n\nExclusion Criteria:\n\n* weight \\> or = 400 lb\n* type 1 or type 2 diabetes\n* patients taking steroid medications\n* anemia\n* heart disease\n* advanced kidney disease (CKD stage 4 and 5)\n* decompensated liver disease\n* hyperthyroidism\n* untreated hypothyroidism\n* active cancer\n* post solid organ or bone marrow transplant\n* HIV\u002FAIDS\n* pregnancy\u002Fplan for pregnancy in the next 6 months\n* breastfeeding\n* post-menopausal women\n* current smoker\n* current recreational drug use\n* night shift or rotating shift workers","50 Years",{"count":435,"type":21},52,[82],"The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?",[25],[150,415,440],"weight gain","2026-02-20",{"date":443,"type":31},"2026-02-24",{"date":445,"type":21},"2026-12-01",{"date":447,"type":21},"2031-11-30",{"name":449,"class":104},"Medical College of Wisconsin",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":458,"minAge":18,"maxAge":301,"enrollmentInfo":459,"targetDuration":4,"studyType":51,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":478,"locationsCount":69},"100584563","frefghterft-lifestyle-coaching-interventions-for-obese-firefighters-firefit-100584563","NCT06890975","\"F!reF!ghterF!t\": Lifestyle Coaching Interventions for Obese Firefighters (FireFit)","\"F!reF!ghterF!t\": A Randomized Controlled Trial of Lifestyle Coaching Interventions for Obese Firefighters","FireFit","Inclusion Criteria:\n\n* Male firefighters aged 18-60 years\n* Currently active as volunteer or career firefighters\n* Body mass index (BMI) ≥30 kg\u002Fm² based on self-reported height and weight\n* Express interest in participating in a clinical study aimed at improving body composition (weight loss), metabolic status, and quality of life\n* Residing and\u002For working in Massachusetts, Rhode Island, or Southern New Hampshire (Boston metro area)\n\nExclusion Criteria:\n\n* Female sex\\*\n* BMI \\\u003C30 kg\u002Fm² based on self-reported height and weight\n* Active psychosis\n* History or diagnosis (during the RCT) of any of the following:\n\nMajor cardiovascular disease event (e.g., myocardial infarction, cardiac arrest, cerebrovascular accident) Cancer (excluding non-melanoma skin cancer) Abnormal liver function (aminotransferase, bilirubin, or alkaline phosphatase ≥3× the upper limit of normal) Renal dysfunction (estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m²)\n\n* Current or recent (within 6 months) use of testosterone treatment or anti-obesity\u002Fobesogenic medications\n* Unwillingness to adhere to potential intervention assignments\n\n  * Because this is an exploratory study, the number of subjects is limited, and men make up roughly 85% of the US fire service, the current proposal is limited to men. In future studies, we will include women firefighters.","MALE",{"count":169,"type":21},[82],"Our goal is to explore the effectiveness of 9- month lifestyle medicine based coaching intervention (individual and group coaching) versus control (usual care\u002F written health instructions). The primary study outcomes will be mean changes in body composition metrics . Secondary outcomes will be the prevalence of metabolic abnormities, progression\u002Fregression of Metabolic Syndrome, push-up \\& sit\u002Fstand capacity, self-reported physical activity, and quality of life\u002Fdiet\u002Fsleep measures.",[25],[150,464,465,466,467,468,469,470,471,472],"firefighters","diabetes mellitus","coaching","healthy lifestyle","lifestyle medicine","metabolic syndrome","quality of life","mental health","physical fitness","2026-02-19",{"date":475,"type":31},"2026-02-23",{"date":311,"type":21},{"date":35,"type":21},{"name":479,"class":104},"Cambridge Health Alliance",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":488,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":51,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":69},"100575172","new-mechanisms-of-obesity-100575172","NCT06768827","New Mechanisms of Obesity","Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications","NMoO","Inclusion Criteria:\n\n* Age 15 to 22 years\n* In puberty (girls and boys: Tanner stage III-V);\n* BMI \\>85th\n\nExclusion Criteria:\n\n* Pregnancy;\n* endocrinopathies (e.g., Cushing syndrome);\n* substance abuse;\n* medications affecting insulin resistance such as metformin, GLP-1 analogues; -\n* high fibers intake (\\> 30g\u002Fday) as assessed by a 3-day food record.","15 Years","22 Years",{"count":491,"type":21},55,[82],"Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.",[87,495,25],"Insulin Resistance",[88,497,495,498],"Youth","Intestinal Fermentation","2026-01-26",{"date":501,"type":31},"2026-01-28",{"date":503,"type":31},"2025-11-13",{"date":375,"type":21},{"name":506,"class":104},"Yale University",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":51,"phases":517,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":69},"100576817","glucose-dependent-insulinotropic-polypeptide-effect-on-bone-remodelling-and-cell-activity-ginebra-100576817","NCT06790225","Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)","GINEBRA","Inclusion Criteria:\n\n* healthy volunteers\n\nExclusion Criteria:\n\n* pre-diabetes or diabetes (HbA1c \\>42mmol\u002Fmol)\n* BMI \\>28\n* fractures with \\\u003C 6months\n* comorbidities\u002Ftreatments that may influence bone metabolism or procedures - -- pregnancy\n* inability to provide informed concent","40 Years",{"count":516,"type":21},12,[82],"Glucose-dependent insulinotropic polypeptide (GIP) is released by the intestines in response to food intake and increases insulin secretion. Although short-term (\\\u003C 3 hours) stimulation with GIP decreases bone resorption in humans, the effect may vanish following continuous administration within 24 hours, at least in patients with type 1 diabetes. Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear. As the first GIP receptor (GIPR) agonist, tirzepatide was recently approved for the treatment of obesity and type 2 diabetes in the USA and type 2 diabetes alone in the EU, there is a need to establish knowledge about the long-term effects of GIP on bone health, including if different exposure times to GIP have different skeletal effects.\n\nThis project will investigate whether GIP maintains its anti-resorptive potential if given as intermittent compared to continuous infusion in healthy men and women aged 18-40 years. Administration cycles involve intermittent (8 hours daily) and continuous (24 hours daily) injection of GIP for three days each. The effect of GIP will be measured by bone markers in blood samples, as well as in vitro activity and genetic alterations of bone cells (osteoclasts and osteoblasts) using bone marrow aspirates and bone marrow biopsies. Each participant will receive both administration cycles using a crossover design with a 14-28 days washout period between administrations of GIP.",[520,521,25],"Bone Disease, Metabolic","Diabetes Mellitus, Type 2",[523,524,525,526,527],"GIP","CTX","P1NP","Glucose-dependent insulinotropic polypeptide","Bone remodelling","2025-12-29",{"date":530,"type":31},"2026-01-02",{"date":532,"type":31},"2025-11-10",{"date":534,"type":21},"2027-11-30",{"name":536,"class":104},"Esbjerg Hospital - University Hospital of Southern Denmark",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":544,"targetDuration":4,"studyType":51,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":69},"100609335","metabolic-effects-of-short-term-ultra-processed-food-intake-mest-upf-100609335","NCT07213245","Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF)","Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF): a Randomized Controlled Trial","Inclusion Criteria:\n\n* Body mass index (BMI) 18.5-30 kg\u002Fm2\n* Fasting glucose \\\u003C 6.1 mmol\u002Fl\n* Hb \\>110 g\u002FL\n* Weight stability the last 3 months +\u002F-5%\n\nExclusion Criteria:\n\n* Food allergies, intolerances or preferences preventing consumption of any products included in the study.\n* Unable to sufficiently understand written and spoken Swedish or English to provide written consent and understand information and instructions from the study personal.\n* Pregnant, lactating or planning a pregnancy during the study period.\n* Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study.\n* History of gastrointestinal conditions or major gastrointestinal surgery (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.).\n* Type 1 diabetes or type 2 diabetes.\n* Thyroid disorder.\n* Current smoking, vaping.\n* Following any weight reduction program or having followed one during the last 6 months prior to screening.\n* Not habitually eating breakfast (\\\u003C5 times\u002Fweek).\n* Restrained eating based on the three-factor eating questionnaire.",{"count":331,"type":21},[82],"The overall aim of this project is to study the effects of short-term high ultra-processed food intake, compared to nutrient- and energy density matched low ultra-processed food (UPF) intake, on energy intake and appetite.\n\nA total of 24 men and women who meet all inclusion criteria and none of the exclusion criteria will be invited to participate. A randomized 2\\*2 factorial four-way crossover study will be conducted at the Department of Internal medicine and Clinical Nutrition at the University of Gothenburg, comparing a high-UPF meal to a low-UPF meal also with high and\u002For low energy density. A supervised breakfast meal will be served, and postprandial blood samples and appetite measures will be collected continuously up to 4 hours after the breakfast meal. Subsequently, an ad libitum lunch meal will be served, and energy intake will be recorded.",[548,25],"Appetite","2025-12-12",{"date":551,"type":31},"2025-12-15",{"date":553,"type":31},"2025-12-01",{"date":555,"type":21},"2026-04-30",{"name":557,"class":104},"Göteborg University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":566,"targetDuration":4,"studyType":51,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":346},"100610618","evaluation-of-cognitive-improvement-after-bariatric-surgery-using-a-virtual-reality-program-and-the-neuropsi-neuropsychological-battery-100610618","NCT07229924","Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery","Effect of Bariatric Surgery on Cognitive Performance Assessed Using a Virtual Reality Program and the Neuropsi Battery.","CognitiveBS","Inclusion Criteria:\n\nA. Age (18-65 years) B. Diagnostic of morbid obesity with a body mass index (BMI) \\> 40 kg\u002Fm2, or, C. Obesity grade II (BMI \\> 35 kg\u002Fm2) and associated comorbidities (Diabetes Mellitus type 2, Hypertension, Ischemic Cardiopathy, Hyperlipidemia, Hepatic Steatosis, Metabolic Syndrome, Obstructive Sleep Apnea, Pickwick Syndrome) D. Bariatric surgery criteria.\n\nExclusion Criteria:\n\nA. Age \\\u003C 18 years, \\> 65 years B. Visual impairment C. Personal history of CVE D. Drug addiction.",{"count":282,"type":21},[82],"Background: Obesity is a chronic, systemic, and multifactorial disease affecting populations worldwide, with projections indicating a 50% increase by 2035. It is linked to higher risks of cognitive decline, brain atrophy, and neurodegenerative diseases like Alzheimer's. Bariatric surgery has shown benefits in reducing fat and systemic inflammation, which may improve cognitive function. However, the factors predicting such improvements remain unclear.\n\nObjective: To evaluate the effect of bariatric surgery on cognitive performance using virtual reality (Neurotracker) and the Neuropsi neuropsychological battery.\n\nMethods: This prospective quasi-experimental study will include patients with morbid obesity who are candidates for bariatric surgery. Cognitive performance will be evaluated using the Neurotracker virtual reality tool and the Neuropsi neuropsychological battery. Participants will complete Neurotracker sessions three times weekly for two weeks before surgery, and again at 3- and 6-months post-surgery. The Neuropsi assessment will be conducted once prior to surgery and repeated at 6 months afterward. Statistical analyses will compare cognitive performance before and after the surgical intervention.\n\nExpected Outcomes: The study aims to identify measurable improvements in cognitive function after weight loss from bariatric surgery, evaluated through both traditional neuropsychological tests and immersive virtual reality tools. These results could improve understanding of the cognitive benefits of surgical obesity treatment and the factors that predict these outcomes.",[570,25],"Obesity (Disorder)",[119,572,573,574,88],"Cognition","NeuroTracker","Neuropsi",{"date":576,"type":31},"2025-11-17",{"date":578,"type":31},"2024-06-25",{"date":580,"type":21},"2026-03-01",{"name":582,"class":583},"Hospital General de México Dr. Eduardo Liceaga","OTHER_GOV",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":328,"minAge":18,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":593,"conditions":594,"keywords":603,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":69},"100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","45 Years",{"count":169,"type":21},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[595,596,597,25,598,599,600,601,602],"Preeclampsia","Preeclampsia (PE)","Preeclampsia (PE) Risk","Pregnancy","Pregnancy Complications","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Gestational Complications",[604,605,606,607,608,609,610,611,612],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":615,"type":31},"2025-09-10",{"date":617,"type":31},"2025-01-01",{"date":619,"type":21},"2028-12-31",{"name":621,"class":104},"University of Tennessee Graduate School of Medicine",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":629,"targetDuration":4,"studyType":51,"phases":631,"briefSummary":632,"conditions":633,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":4},"100600718","precision-nutrition-technologies-for-obesity-management-100600718","NCT07101133","Precision Nutrition Technologies for Obesity Management","Research on Key Technologies of Precision Nutrition for Obesity Intervention","Inclusion Criteria:18 years old to 60 years old, gender not limited. Obesity diagnosis standard, 28≤ BMI (kg\u002Fm2)≤ 35 ; Signed informed consent;\n\nExclusion Criteria:Secondary obesity caused by endocrine, genetic, central nervous system diseases or drugs; Merge major disease, tumor, each system organ failure; Had serious infection and acute cardiocerebrovascular diseases; Over the past three months in three months, or drug or surgical treatment has been put on a diet; Pregnancy, for pregnant and nursing women; Mental disorders, or physical\u002Fbody movement disorders affect normal activities; 5 kg weight fluctuation in the past two months; Daily alcohol consumption quantity more than 25 g for man, women more than 15 g.",{"count":630,"type":21},600,[82],"The implementation of this project will develop and apply precision health dietary solutions tailored for weight management in China's obese population, establishing a precision nutrition intervention model. Over 50% of the obese individuals are expected to achieve a weight reduction of more than 5%, significantly improving their quality of life.",[25],"2025-07-31",{"date":636,"type":31},"2025-08-03",{"date":638,"type":21},"2025-07-27",{"date":640,"type":21},"2027-06-30",{"name":642,"class":104},"Yuan He",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":355,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":653,"conditions":654,"keywords":658,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":666,"locationsCount":69},"100429529","development-of-a-non-invasive-screening-tool-to-predict-metabolic-dysfunction-associated-steatotic-liver-disease-100429529","NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","MASLD","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices",{"count":652,"type":21},2000,"A generic screening study to establish structural and\u002For functional baselines of specific organs.",[655,656,649,657,25],"Healthy","Fatty Liver","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease",[659,649],"Fatty liver","2025-07-18",{"date":662,"type":31},"2025-07-23",{"date":664,"type":31},"2019-09-27",{"date":424,"type":21},{"name":667,"class":38},"Richmond Research Institute",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":674,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":328,"minAge":18,"maxAge":113,"enrollmentInfo":676,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":678,"conditions":679,"keywords":686,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":69},"100588716","monitoring-nutritional-consequences-of-obesity-treatment-on-womens-health-100588716","NCT06945016","Monitoring Nutritional Consequences of Obesity Treatment on Women's Health","MOnitoring NUtritional COnsequences of Obesity Treatment on Women's Health and Transgenerational Effects for Healthier Future Generations: a Multicentre Prospective Observational Cohort Study","MONUCO","General Inclusion Criteria:\n\n* Female sex at birth\n* Aged 18-55 years of age\n* Living with obesity (BMI ≥ 30 kg\u002Fm2)\n* Approved for obesity treatment in one of the participating hospitals:\n* Undergoing primary bariatric surgery (RYGB, OAGB or SG)\n* Receiving obesity medication (any type) with a BMI ≥30 kg\u002Fm2 under medical supervision.\n* For those undergoing MRI, DEXA and quantitative ultrasound scan: Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician.\n\nAdditional inclusion criteria for birth cohort:\n\n* Being pregnant\n* Age 18-45 years of age\n* Having received prior obesity treatment, either surgical (RYGB, OAGB, SG) or pharmacological for at least 4 months under medical supervision (any type).\n\nGeneral Exclusion Criteria:\n\n* Male sex at birth\n* Aged \\\u003C18 or \\>55 years of age\n* BMI \\\u003C30 kg\u002Fm2\n* Not able to read and\u002For write in Dutch\n* Undergoing a revisional or secondary bariatric procedure (excluding previous gastric banding)\n* Malnutrition due to other chronic condition, specifically malignancy, substance abuse\n* (mental) condition that makes it impossible to fill out a questionnaire correctly.\n* For those undergoing a DEXA scan: height \\>196 cm or weight \\>160 kg\n* For those undergoing a MRI scan: having a contra-indication to MRI scanning including (but not limited to) pacemakers and defibrillators, intraorbital or intraocular metallic fragments, ferromagnetic implans or claustrophobia.\n\nAdditional exclusion criteria birth cohort:\n\n* Aged \\\u003C18 or \\>45 years of age\n* \\>25 weeks of gestation\n* Multiple pregnancy\n* Reversal of the bariatric procedure",{"count":677,"type":21},1150,"The goal of this observational study is to investigate the long-term effect of obesity treatments on the health of women. This study will specifically focusses on the effects on nutritional intake, nutritional status, musculoskeletal health and reproductive health. Additionally, this study will also investigate the effect of obesity treatment on pregnancy outcomes and child development.\n\nTo achieve the goal of this study, participants already receiving either surgical treatment for obesity or treatment with anti-obesity medication as part of their regular medical care will fill in additional questionnaires, provide blood, urine and feces samples, and undergo additional measurements of body composition and muscle strength up to for 10 years.",[25,119,680,681,682,683,684,598,685],"Anti-obesity Agents","Body Composition","Muscle Strength","Reproductive Health","Mental Health","Nutritional Status",[687,688,150,689,690,691,692,693],"cohort","obesity treatment","Bariatric surgery","anti-obesity agents","body composition","nutrition","observational","2025-07-06",{"date":696,"type":31},"2025-07-10",{"date":698,"type":31},"2025-01-28",{"date":700,"type":21},"2040-01-28",{"name":702,"class":104},"Wageningen University and Research"]